Register / Log in
Live Now

Browse a library of on-demand videos including clinical case studies, focused presentations and past webcasts

DS
LGS
Paediatric (<16 years old)
Transition (16–18 years old)
Adult (>18 years old)
Full webcast
Impact of COVID-19
Selim Benbadis (USA)
Ulrich Brandl (DE)
Richard Chin (UK)
Angela Kaindl (DE)
Andreas Schulze-Bonhage (DE)
Elizabeth Thiele (USA)
Bernhard Steinhoff (DE)
Sameer Zuberi (UK)
Nick Jones (UK)

DIAGNOSIS AND MANAGEMENT OF LGS AND DS

../assets/websitedata/webcast.gw-pharma.com/Files/videos/Section1_1.mp4

Epilepsy care and implications for GW CBD treatment in the times of COVID-19

All

Epilepsy care and implications for GW CBD treatment in the times of COVID-19

Panel discussion: The panel discuss how they have adapted their working practices during the COVID-19 pandemic, such as virtual meetings with patients, and highlight the advantages and disadvantages of these new ways of working. They also consider the impact of these changes on future patient care.

Source:  Focus webcast 3 (2 September 2020)

Register / Log in to watch
Epilepsy care and implications for GW CBD treatment in the times of COVID-19

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section1_2.mp4

Challenges and solutions in managing patients with refractory epilepsy (during the COVID-19 pandemic): Richard Chin

Richard FM Chin

Challenges and solutions in managing patients with refractory epilepsy (during the COVID-19 pandemic): Richard Chin

Presentation: Prof. Richard Chin talks about the challenges his team faced during the COVID-19 pandemic and solutions they developed to facilitate remote consultations and monitoring. This includes vCreate, a cloud-based bidirectional video interface securing asynchronous video transfer, classification and storage for neurological care.

Register / Log in to watch
Challenges and solutions in managing patients with refractory epilepsy (during the COVID-19 pandemic): Richard Chin

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section1_3.mp4

Syndromic diagnosis of LGS: Sameer Zuberi

Syndromic diagnosis of LGS: Sameer Zuberi

Presentation: Prof. Sameer Zuberi describes the updated International League Against Epilepsy definition of LGS, including mandatory criteria such as seizure type and EEG features. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)
 

Register / Log in to watch
Syndromic diagnosis of LGS: Sameer Zuberi

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section1_D.mp4

Syndromic diagnosis of LGS: Ulrich Brandl

Ulrich Brandl

Syndromic diagnosis of LGS: Ulrich Brandl

Presentation: Prof. Ulrich Brandl describes the presentation of LGS from a paediatric neurologist's perspective and provides an overview of the evolving clinical condition of LGS. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Register / Log in to watch
Syndromic diagnosis of LGS: Ulrich Brandl

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section1_E.mp4

Syndromic diagnosis of LGS: Selim Benbadis

Selim Benbadis

Syndromic diagnosis of LGS: Selim Benbadis

Presentation and case study: Prof. Selim Benbadis discusses the presentation of LGS and its challenges from an adult neurologist's perspective, and highlights important considerations using a clinical case of a 26-year-old male patient. Followed by a Q&A discussion. 

Source: Focus webcast 5 (10 December 2020)

Register / Log in to watch
Syndromic diagnosis of LGS: Selim Benbadis

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section1_F.mp4

Clinical management of LGS and DS from childhood to adolescence and adulthood: Bernhard Steinhoff

Bernhard Steinhoff

Clinical management of LGS and DS from childhood to adolescence and adulthood: Bernhard Steinhoff

Presentation: Prof. Bernhard Steinhoff summarises the current treatment guidelines for LGS and DS and discusses the journey of patients with LGS and DS from childhood to adulthood, including age-related treatment considerations and challenges for caregivers and neurologists.

Register / Log in to watch
Clinical management of LGS and DS from childhood to adolescence and adulthood: Bernhard Steinhoff

There are no results for your specified filter.

Starting and maintaining patients on GW CBD

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_A.mp4

Starting and maintaining patients on GW CBD: Angela Kaindl (Case 1)

Angela M Kaindl

Starting and maintaining patients on GW CBD: Angela Kaindl (Case 1)

Presentation: Prof. Angela Kaindl presents an overview of her centre's experience with GW CBD in 28 paediatric patients with LGS. Dosage and titration of GW CBD and short-term observations, including adverse effects, both positive and negative are covered. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
Starting and maintaining patients on GW CBD: Angela Kaindl (Case 1)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_B.mp4

Starting and maintaining patients on GW CBD: Selim Benbadis (Case 1)

Selim Benbadis

Starting and maintaining patients on GW CBD: Selim Benbadis (Case 1)

Case study: Prof. Selim Benbadis presents a clinical case of a 25-year-old female patient with LGS, describing the diagnosis of LGS and the introduction and slow titration of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
Starting and maintaining patients on GW CBD: Selim Benbadis (Case 1)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_C.mp4

Starting and maintaining patients on GW CBD: Angela Kaindl (Case 2)

Angela M Kaindl

Starting and maintaining patients on GW CBD: Angela Kaindl (Case 2)

Case study: Prof. Angela Kaindl presents a clinical case of a 13-year-old female patient with LGS (ANKRD11 mutation) who was initiated on 2 mg/kg/day GW CBD, which was titrated up weekly to a dose of 15 mg/kg/day. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
Starting and maintaining patients on GW CBD: Angela Kaindl (Case 2)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_D.mp4

Starting and maintaining patients on GW CBD: Selim Benbadis (Case 2)

Selim Benbadis

Starting and maintaining patients on GW CBD: Selim Benbadis (Case 2)

Case study: Prof. Selim Benbadis describes a clinical case of a 15-year-old female patient with LGS who had previously been taking a non-regulatory approved cannabis-based product prior to receiving GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
Starting and maintaining patients on GW CBD: Selim Benbadis (Case 2)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_E.mp4

Initiating patients with GW CBD: Elizabeth Thiele

Elizabeth Thiele

Initiating patients with GW CBD: Elizabeth Thiele

Case study: Prof. Elizabeth Thiele presents a clinical case demonstrating the reintroduction of clobazam prior to initiation of GW CBD in a 12-year-old male patient with LGS. Clobazam had initially been withdrawn due to minimal efficacy and poor tolerability. Followed by a Q&A discussion.

Source: Focus webcast 3 (2 September 2020)

Register / Log in to watch
Initiating patients with GW CBD: Elizabeth Thiele

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_F.mp4

Initiating patients with GW CBD: Angela Kaindl

Angela M Kaindl

Initiating patients with GW CBD: Angela Kaindl

Case study: Prof. Angela Kaindl presents two clinical case studies, one of a 6-year-old female patient with LGS and one of a 9-year-old male patient with LGS, demonstrating how patients may respond differently following initiation of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Initiating patients with GW CBD: Angela Kaindl

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_G.mp4

Initiating patients with GW CBD: Ulrich Brandl

Ulrich Brandl

Initiating patients with GW CBD: Ulrich Brandl

Case study: Prof. Ulrich Brandl presents a clinical case of an 8-year-old male patient with LGS who exhibited behavioural problems prior to initiation and titration of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Initiating patients with GW CBD: Ulrich Brandl

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_H.mp4

Initiating patients with GW CBD: Selim Benbadis

Selim Benbadis

Initiating patients with GW CBD: Selim Benbadis

Case study: Prof. Selim Benbadis presents a clinical case describing the initiation of GW CBD in a 26-year-old male patient with LGS secondary to Down's syndrome. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Initiating patients with GW CBD: Selim Benbadis

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_I.mp4

From paediatric to adolescent/adult care: Angela Kaindl

Angela M Kaindl

From paediatric to adolescent/adult care: Angela Kaindl

Case study: Prof. Angela Kaindl presents a clinical case describing the introduction and dose management of GW CBD in a 9-year-old male patient with LGS. Followed by a Q&A discussion with Prof. Selim Benbadis who had presented a case study on an adult male patient with LGS.

Source: Focus webcast 3 (2 September 2020)

Register / Log in to watch
From paediatric to adolescent/adult care: Angela Kaindl

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_J.mp4

From paediatric to adolescent/adult care: Selim Benbadis

Selim Benbadis

From paediatric to adolescent/adult care: Selim Benbadis

Case study: Prof. Selim Benbadis presents a clinical case of a 19-year-old male patient with LGS, describing the diagnosis of LGS and the introduction of GW CBD. Followed by a Q&A discussion with Prof. Angela Kaindl who had presented a case study on a paediatric male patient with LGS.

Source: Focus webcast 3 (2 September 2020)

Register / Log in to watch
From paediatric to adolescent/adult care: Selim Benbadis

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_K.mp4

GW CBD patient profile: Elizabeth Thiele (Case 1)

Elizabeth Thiele

GW CBD patient profile: Elizabeth Thiele (Case 1)

Case study: Prof. Elizabeth Thiele presents a patient profile, describing the introduction of GW CBD in a 22-year-old female patient with DS who was refractory to multiple ASMs. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
GW CBD patient profile: Elizabeth Thiele (Case 1)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_L.mp4

GW CBD patient profile: Elizabeth Thiele (Case 2)

Elizabeth Thiele

GW CBD patient profile: Elizabeth Thiele (Case 2)

Case study: Prof. Elizabeth Thiele presents a clinical case describing the initiation of GW CBD in a 5-year-old male patient with DS. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
GW CBD patient profile: Elizabeth Thiele (Case 2)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section2_M.mp4

GW CBD patient profile: Bernhard Steinhoff (Case 2)

Bernhard Steinhoff

GW CBD patient profile: Bernhard Steinhoff (Case 2)

Case study: Prof. Bernhard Steinhoff presents a clinical case describing the partial initial efficacy following initiation of GW CBD in a 22-year-old male patient with DS who had been refractory to many other ASMs. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
GW CBD patient profile: Bernhard Steinhoff (Case 2)

There are no results for your specified filter.

Managing adverse events and DDIs

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_A.mp4

Managing adverse events: Elizabeth Thiele (Case 1)

Elizabeth Thiele

Managing adverse events: Elizabeth Thiele (Case 1)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 19-year-old male patient with LGS, and describes the management of adverse events, including lethargy and decreased appetite. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
Managing adverse events: Elizabeth Thiele (Case 1)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_B.mp4

Managing adverse events: Elizabeth Thiele (Case 2)

Elizabeth Thiele

Managing adverse events: Elizabeth Thiele (Case 2)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 10-year-old male patient with DS who experienced diarrhoea due to a sesame oil allergy. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
Managing adverse events: Elizabeth Thiele (Case 2)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_C.mp4

Managing adverse events with GW CBD: Elizabeth Thiele (Case 3)

Elizabeth Thiele

Managing adverse events with GW CBD: Elizabeth Thiele (Case 3)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 25-year-old female patient with LGS in the setting of tuberous sclerosis complex who experienced behavioural problems due to a suspected DDI. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Register / Log in to watch
Managing adverse events with GW CBD: Elizabeth Thiele (Case 3)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_D.mp4

Managing adverse events: Andreas Schulze-Bonhage (Case 1)

Andreas Schulze-Bonhage

Managing adverse events: Andreas Schulze-Bonhage (Case 1)

Case study: Prof. Andreas Schulze-Bonhage presents a clinical case of a 30-year-old male patient with LGS. He describes the management of adverse events, including nausea, vomiting and elevated transaminase levels. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
Managing adverse events: Andreas Schulze-Bonhage (Case 1)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_E.mp4

Managing adverse events: Andreas Schulze-Bonhage (Case 2)

Andreas Schulze-Bonhage

Managing adverse events: Andreas Schulze-Bonhage (Case 2)

Case study: Prof. Andreas Schulze-Bonhage presents a clinical case of a 31-year-old male patient with LGS with idiosyncratic intolerability due to a specific genetic defect in CBD metabolism. The patient experienced difficulties in concentration and double vision when taking GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
Managing adverse events: Andreas Schulze-Bonhage (Case 2)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_F.mp4

Managing adverse events: Sameer Zuberi

Managing adverse events: Sameer Zuberi

Case study: Prof. Sameer Zuberi presents a clinical case of a 15-year-old female patient with DS who experienced diarrhoea following introduction of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Managing adverse events: Sameer Zuberi

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_G.mp4

Managing adverse events: Bernhard Steinhoff (Case 1)

Bernhard Steinhoff

Managing adverse events: Bernhard Steinhoff (Case 1)

Case study: Prof. Bernhard Steinhoff presents a clinical case of a 28-year-old female patient with LGS who experienced increased sedation following introduction of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Managing adverse events: Bernhard Steinhoff (Case 1)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_H.mp4

Managing adverse events with GW CBD: Bernhard Steinhoff (Case 2)

Bernhard Steinhoff

Managing adverse events with GW CBD: Bernhard Steinhoff (Case 2)

Case study: Prof. Bernhard Steinhoff presents a clinical case of a 34-year-old male patient with LGS who experienced somnolence after introduction of GW CBD and clobazam. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Register / Log in to watch
Managing adverse events with GW CBD: Bernhard Steinhoff (Case 2)

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_I.mp4

Polytherapy and monitoring requirements with GW CBD: Sameer Zuberi

Polytherapy and monitoring requirements with GW CBD: Sameer Zuberi

Presentation and case study: Prof. Sameer Zuberi presents an overview of polytherapy in LGS and DS. He also covers potential DDIs with GW CBD and common ASMs. He also provides an overview of the additional monitoring required with GW CBD, which he illustrates using a clinical case of a 4-year-old female patient with LGS. Followed by a Q&A discussion.

Source: Focus webcast 3 (2 September 2020)

Register / Log in to watch
Polytherapy and monitoring requirements with GW CBD: Sameer Zuberi

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_J.mp4

Implications of polytherapy in LGS for GW CBD: Ulrich Brandl

Ulrich Brandl

Implications of polytherapy in LGS for GW CBD: Ulrich Brandl

Presentation: Prof. Ulrich Brandl describes the implications of polytherapy in LGS for GW CBD, including a summary of DDIs, clinical problems and recommendations for the introduction of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Register / Log in to watch
Implications of polytherapy in LGS for GW CBD: Ulrich Brandl

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_K.mp4

Implications of polytherapy in LGS for GW CBD: Bernhard Steinhoff

Bernhard Steinhoff

Implications of polytherapy in LGS for GW CBD: Bernhard Steinhoff

Case study: Prof. Bernhard Steinhoff describes the follow up required, in case of possible DDIs, in a clinical case of a 27-year-old male patient with LGS on a baseline combination of high-dose valproate, lamotrigine, and brivaracetam upon initiation of low dose clobazam and GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Register / Log in to watch
Implications of polytherapy in LGS for GW CBD: Bernhard Steinhoff

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section3_L.mp4

GW CBD patient profile: Bernhard Steinhoff (Case 1)

Bernhard Steinhoff

GW CBD patient profile: Bernhard Steinhoff (Case 1)

Case study: Prof. Bernhard Steinhoff presents his experience of managing a 27-year-old male patient with DS who experienced drug- and diet-resistant diarrhoea when taking GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
GW CBD patient profile: Bernhard Steinhoff (Case 1)

There are no results for your specified filter.

GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section4_A.mp4

GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Ulrich Brandl

Ulrich Brandl

GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Ulrich Brandl

Presentation: Prof. Ulrich Brandl discusses the key considerations for introducing GW CBD in patients who have previously been taking non-regulatory approved cannabis-based products. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Register / Log in to watch
GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Ulrich Brandl

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section4_B.mp4

GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Selim Benbadis

Selim Benbadis

GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Selim Benbadis

Case study: Prof. Selim Benbadis presents a clinical case of a 42-year-old male patient with LGS who initiated GW CBD after weaning off a non-regulatory approved cannabis-based product from a ‘dispensary’ at an unclear dose (< 10 mg daily). Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Selim Benbadis

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section4_C.mp4

Initiating GW CBD in patients who have previously received a non-regulatory approved cannabis-based product: Selim Benbadis

Selim Benbadis

Initiating GW CBD in patients who have previously received a non-regulatory approved cannabis-based product: Selim Benbadis

Case study: Prof. Selim Benbadis describes a clinical case of a 28-year-old patient who initiated GW CBD following discontinuation of an unknown dose of non-regulatory approved cannabis-based product from a ‘dispensary’. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Initiating GW CBD in patients who have previously received a non-regulatory approved cannabis-based product: Selim Benbadis

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section4_D.mp4

Shared clinical experience: patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Selim Benbadis

Selim Benbadis

Shared clinical experience: patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Selim Benbadis

Case study: Prof. Selim Benbadis discusses how GW CBD might be introduced in a patient who is currently receiving non-regulatory approved cannabis-based products through an illustrative clinical case study of a 7-year-old female patient.

Register / Log in to watch
Shared clinical experience: patients who have tried or are currently receiving non-regulatory approved cannabis-based products: Selim Benbadis

There are no results for your specified filter.

Determining the optimal use of GW CBD

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section5_A.mp4

Considerations for dosing and medication combinations with GW CBD

All

Considerations for dosing and medication combinations with GW CBD

Panel discussion: The panel address three questions from the audience covering which seizures respond best to GW CBD, the optimal dose of GW CBD, and whether there is any benefit to combining specific drugs with GW CBD.

Source: Focus webcast 2 (2 July 2020)

Register / Log in to watch
Considerations for dosing and medication combinations with GW CBD

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section5_B.mp4

Determining the optimal dose of GW CBD: Elizabeth Thiele

Elizabeth Thiele

Determining the optimal dose of GW CBD: Elizabeth Thiele

Case study: Prof. Elizabeth Thiele presents a clinical case of a 16-year-old female patient with LGS and describes the process of determining the optimal dose of GW CBD by reviewing the dosage and titration of clobazam and GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Determining the optimal dose of GW CBD: Elizabeth Thiele

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section5_C.mp4

Determining the optimal dose of GW CBD: Bernhard Steinhoff

Bernhard Steinhoff

Determining the optimal dose of GW CBD: Bernhard Steinhoff

Case study: Prof. Bernhard Steinhoff presents a clinical case describing the initiation of low-dose clobazam and titration of GW CBD in a 32-year-old male patient with LGS . Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Determining the optimal dose of GW CBD: Bernhard Steinhoff

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section5_D.mp4

Early versus late intervention with GW CBD

All

Early versus late intervention with GW CBD

Panel discussion: The panel discuss the placement of GW CBD in the treatment algorithms for LGS and DS, and the possibilities of it being used as an early intervention. The challenges surrounding syndromic diagnosis is highlighted as a barrier to early intervention.

Source: Focus webcast 4 (23 September 2020)

Register / Log in to watch
Early versus late intervention with GW CBD

There are no results for your specified filter.

Cannabinoid science

../assets/websitedata/webcast.gw-pharma.com/Files/videos/section6_A.mp4

Cannabinoid science: what is cannabidiol (CBD)?: Nick Jones

Nick Jones

Cannabinoid science: what is cannabidiol (CBD)?: Nick Jones

Presentation: Nick Jones, PhD, discusses developments in cannabinoid medical research, regulatory versus non-regulatory approved cannabis-based products, and the molecular pharmacology and proposed mechanism of action of CBD in epilepsy.

Register / Log in to watch
Cannabinoid science: what is cannabidiol (CBD)?: Nick Jones

There are no results for your specified filter.

Full webcasts

../assets/websitedata/webcast.gw-pharma.com/Files/webcast_1.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 4 June 2020

All

0

Welcome and introduction

285

GW CBD patient profile (case studies)

710

GW CBD patient profile (discussion)

1164

Starting and maintaining patients on GW CBD (case studies)

1683

Starting and maintaining patients on GW CBD (discussion)

2137

Managing adverse events (case studies)

2628

Managing adverse events (discussion)

3049

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (case studies)

3649

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (discussion)

4446

Summary and close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 4 June 2020

During this webcast, the expert faculty discussed:

  • GW CBD patient profile 
  • Starting and maintaining patients on GW CBD
  • Managing adverse events associated with GW CBD 
  • GW CBD in patients who have tried or who are currently receiving unlicensed cannabis-based products
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 4 June 2020

https://epilepsy-focus.co.uk/assets/websitedata/webcast.gw-pharma.com/Files/webcast_2.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 2 July 2020

All

0

Welcome and introduction

270

GW CBD patient profile (case studies)

677

GW CBD patient profile (discussion)

1154

Starting and maintaining patients on GW CBD (case studies)

1627

Starting and maintaining patients on GW CBD (discussion)

2084

Managing adverse events (case studies)

2637

Managing adverse events (discussion)

3031

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (case studies)

3633

GW CBD in patients who have tried or are currently receiving unlicensed cannabis-based products (discussion)

4015

General open discussion

4403

Summary and close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 2 July 2020

During this webcast, the expert faculty discussed:

  • GW CBD patient profile 
  • Starting and maintaining patients on GW CBD
  • Managing adverse events associated with GW CBD 
  • GW CBD in patients who have tried or who are currently receiving unlicensed cannabis-based products
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 2 July 2020

../assets/websitedata/webcast.gw-pharma.com/Files/HEL-153806-EpilepsyFocusWebcast3-V3a.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 2 September 2020

All

0

Welcome, introduction and agenda

258

Initiating patients with GW CBD (case studies)

960

Initiating patients with GW CBD (discussion)

1210

Polytherapy and monitoring requirements with GW CBD (presentation and case study)

1908

Polytherapy and monitoring requirements with GW CBD (discussion)

2164

From paediatric to adolescent/adult care (case studies)

2772

From paediatric to adolescent/adult care (discussion)

3081

Epilepsy care and implications for GW CBD treatment in the times of COVID-19 (panel discussion)

4198

Meeting close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 2 September 2020

During this webcast, the expert faculty discussed: 

  • Identifying patients that might benefit from GW CBD
  • Reintroducing clobazam in patients who have previously tried and discontinued clobazam
  • Polytherapy and monitoring requirements
  • Transition from paediatric to adolescent/adult care
  • Epilepsy care and implications for GW CBD treatment in the times of COVID-19
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 2 September 2020

../assets/websitedata/webcast.gw-pharma.com/Files/webcast4.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020

All

0

Welcome, introduction and agenda

289

Initiating patients with GW CBD (case studies)

1242

Initiating patients with GW CBD (discussion)

1540

Managing adverse events (case studies)

1993

Managing adverse events (discussion)

2365

Determining the optimal dose of GW CBD (case studies)

3130

Determining the optimal dose of GW CBD (discussion)

3379

Initiating GW CBD in patients who have previously received non-regulatory approved cannabis-based products (case studies)

3790

Initiating GW CBD in patients who have previously received non-regulatory approved cannabis-based products (discussion)

4030

Panel discussion: Early versus late intervention with GW CBD

4560

Summary and close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020

During this webcast, the expert faculty discussed:

  • When to consider GW CBD
  • The importance of diagnosis: LGS in adult patients
  • Managing adverse events associated with GW CBD
  • Determining the optimal dose of GW CBD 
  • Initiating GW CBD in patients who have tried or who are currently receiving non-regulatory approved cannabis-based products
  • Early versus late intervention with GW CBD
     
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020

../assets/websitedata/webcast.gw-pharma.com/Files/201218_Webcast10dec.mp4

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 10 December 2020

All

0

Welcome, introduction and agenda

307

Managing adverse events with GW CBD: behavioural and cognitive problems

1226

Managing adverse events with GW CBD: behavioural and cognitive problems (discussion)

1433

Implications of polytherapy in LGS for GW CBD

2206

Implications of polytherapy in LGS for GW CBD (discussion)

2512

Syndromic diagnosis of LGS

3673

Syndromic diagnosis of LGS (discussion)

4429

Meeting close

Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 10 December 2020

This webcast focused on the diagnosis and management of patients with LGS. The expert faculty discussed:

  • The importance of diagnosis in patients with LGS, including syndromic diagnoses
  • Cognitive and behavioural problems in patients with LGS receiving GW CBD
  • How to best manage polytherapy in patients with LGS receiving GW CBD
  • The evolution of LGS and implications for treatment, as well as diagnosis in adult patients
Register / Log in to watch
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Thursday 10 December 2020

There are no results for your specified filter.

Abbreviations:
ASMs, antiseizure medications; DDI, drug-drug interaction; DS, Dravet syndrome; CBD, cannabidiol; EEG, electroencephalogram; LGS, Lennox-Gastaut syndrome

Login

Already registered?
Log in using your email address.

REGISTER

New to this platform?
Click below to register and to gain access to our on-demand videos and Epidyolex® (cannabidiol) shared experience webcasts.
Register now

Register for our Epidyolex®(cannabidiol) shared experience webcasts

Enter your details below to register. Did you already register? Click here to login.

Personal info *

Webcast info

Legal info

Next step

Thanks for registering

Thanks for registering. Please check your email to verify your account. If you don't receive this email shortly, please check your spam folder.

The email will contain further instructions.

Thanks for submitting a question

Thank you for submitting your question.

All questions will be collated and directed to the relevant speaker(s) for discussion in the live webcasts.
 

Welcome to the GW Pharmaceuticals Epilepsy Focus microsite!

This microsite is intended for UK healthcare professionals only.
Please confirm that you are a registered UK healthcare professional.


Welcome to GW Pharmaceuticals Epilepsy Focus microsite!

Thank you for visiting our microsite.

Please note that this microsite is only accessible to UK healthcare professionals.
For more information about GW Pharmaceuticals, please visit our corporate website.

 
 

You are about to leave this website

Please note this link will redirect you to an external website.

Please confirm if you are happy to continue.

Please note this link will redirect you to an external website.

Please confirm if you are happy to continue.

Continue Cancel
 
 

CONFIRM YOUR EMAIL ADDRESS

Thank you for completing this form. Please note that you are not yet fully registered. You will receive an email to your email address from noreply@epilepsy-focus.co.uk with a confirmation link. In order to complete the registration process and gain full access to our e-learning videos and webcasts, please click the link in your confirmation email.

If you do not receive a confirmation email, please check your spam folder. Also, please verify that you entered a valid email address in our sign-up form.

If you need assistance, please contact support-focus@gwpharm.com

I Understand
 
 

THANKS FOR SUBMITTING A QUESTION

Thank you for submitting your question.

All questions will be collated and directed to the relevant speaker(s) for discussion in the live webcasts.

Close
 
 

EPILEPSY FOCUS WEBSITE UPDATE

After listening to your feedback and thoughts on learning preferences, we have updated our Epilepsy FOCUS website to now function exclusively as an on-demand platform!

We encourage you to browse our extensive library of engaging and informative on-demand videos, including case studies, focused presentations and full past webcasts.

New on-demand videos will also be added to the platform over the coming months; we will inform you via email when they become available to view.

Please visit the 'About' page for more information on the videos and how to use the new search tool function to identify the content most relevant to you.

Continue
 
Please use a larger browser window for a better website experience.